{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T22:53:01Z","timestamp":1777330381468,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - General Subjects"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.bbagen.2021.129929","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T11:49:54Z","timestamp":1620820194000},"page":"129929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Human cancer xenografts in immunocompromised mice provide an advanced genuine tumor model for research and drug development-A revisit of murine models for human cancers"],"prefix":"10.1016","volume":"1865","author":[{"given":"Quan-en","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbagen.2021.129929_bb0005","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ceb.2009.01.014","article-title":"The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl","volume":"21","author":"Eck","year":"2009","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.bbagen.2021.129929_bb0010","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of cd19 car therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbagen.2021.129929_bb0015","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/1078-0432.971.11.3","article-title":"50 years of preclinical anticancer drug screening: empirical to target-driven approaches","volume":"11","author":"Suggitt","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbagen.2021.129929_bb0020","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2353\/ajpath.2007.060929","article-title":"Murine models to evaluate novel and conventional therapeutic strategies for cancer","volume":"170","author":"Talmadge","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbagen.2021.129929_bb0025","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1017\/S0016672300010168","article-title":"\u2018Nude\u2019, a new hairless gene with pleiotropic effects in the mouse","volume":"8","author":"Flanagan","year":"1966","journal-title":"Genet. Res."},{"key":"10.1016\/j.bbagen.2021.129929_bb0030","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/301527a0","article-title":"A severe combined immunodeficiency mutation in the mouse","volume":"301","author":"Bosma","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.bbagen.2021.129929_bb0035","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/335256a0","article-title":"Transfer of a functional human immune system to mice with severe combined immunodeficiency","volume":"335","author":"Mosier","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.bbagen.2021.129929_bb0040","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood-2005-02-0516","article-title":"Development of functional human blood and immune systems in NOD\/SCID\/IL2 receptor {gamma} chain(null) mice","volume":"106","author":"Ishikawa","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbagen.2021.129929_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1054-3589(08)60263-X","article-title":"Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976\u20131982, and future directions","volume":"20","author":"Venditti","year":"1984","journal-title":"Adv. Pharmacol. Chemother."},{"key":"10.1016\/j.bbagen.2021.129929_bb0050","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2889","article-title":"Choosing the right cell line for breast cancer research","volume":"13","author":"Holliday","year":"2011","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bbagen.2021.129929_bb0055","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1158\/2159-8290.CD-18-0044","article-title":"Mouse models for cancer immunotherapy research","volume":"8","author":"Olson","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbagen.2021.129929_bb0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem cells, cancer, and cancer stem cells","volume":"414","author":"Reya","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.bbagen.2021.129929_bb0065","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","article-title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","volume":"351","author":"Cristofanilli","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bbagen.2021.129929_bb0070","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz026","article-title":"Circulating tumor cells in early breast cancer","volume":"3","author":"Thery","year":"2019","journal-title":"JNCI Cancer Spectr."},{"key":"10.1016\/j.bbagen.2021.129929_bb0075","doi-asserted-by":"crossref","first-page":"12383","DOI":"10.18632\/oncotarget.2592","article-title":"Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model","volume":"5","author":"Zhang","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbagen.2021.129929_bb0080","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective identification of tumorigenic breast cancer cells","volume":"100","author":"Al-Hajj","year":"2003","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1016\/j.bbagen.2021.129929_bb0085","doi-asserted-by":"crossref","first-page":"948501","DOI":"10.1155\/2015\/948501","article-title":"Human tumor antigens and cancer immunotherapy","volume":"2015","author":"Vigneron","year":"2015","journal-title":"Biomed Res Int."},{"key":"10.1016\/j.bbagen.2021.129929_bb0090","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0091-679X(08)00014-9","article-title":"Isolation and culture of colon cancer stem cells","volume":"86","author":"Cammareri","year":"2008","journal-title":"Methods Cell Biol."},{"key":"10.1016\/j.bbagen.2021.129929_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2010\/617421","article-title":"Significance of circulating tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer","volume":"2010","author":"Miller","year":"2010","journal-title":"J. Oncol."},{"key":"10.1016\/j.bbagen.2021.129929_bb0100","doi-asserted-by":"crossref","first-page":"76337","DOI":"10.18632\/oncotarget.10942","article-title":"Targeting signal transduction pathways of cancer stem cells for therapeutic opportunities of metastasis","volume":"7","author":"Iqbal","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbagen.2021.129929_bb0105","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.cell.2009.08.017","article-title":"Heterogeneity in cancer: cancer stem cells versus clonal evolution","volume":"138","author":"Shackleton","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.bbagen.2021.129929_bb0110","doi-asserted-by":"crossref","first-page":"27301","DOI":"10.1038\/srep27301","article-title":"High-throughput single-cell derived sphere formation for cancer stem-like cell identification and analysis","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbagen.2021.129929_bb0115","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.it.2020.06.010","article-title":"Organoid models of tumor immunology","volume":"41","author":"Yuki","year":"2020","journal-title":"Trends Immunol."},{"key":"10.1016\/j.bbagen.2021.129929_bb0120","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40169-018-0198-1","article-title":"The role of\u00a0CD133 in\u00a0cancer: a\u00a0concise review","volume":"7","author":"Glumac","year":"2018","journal-title":"Clin. Trans. Med."},{"key":"10.1016\/j.bbagen.2021.129929_bb0125","doi-asserted-by":"crossref","first-page":"285","DOI":"10.5483\/BMBRep.2017.50.6.039","article-title":"Cancer stem cell surface markers on normal stem cells","volume":"50","author":"Kim","year":"2017","journal-title":"BMB Rep."},{"key":"10.1016\/j.bbagen.2021.129929_bb0130","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","article-title":"Patient derived xenograft models: an emerging platform for translational cancer research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discov."},{"issue":"17","key":"10.1016\/j.bbagen.2021.129929_bb0135","article-title":"Patient-derived xenografts: a valuable platform for clinical and preclinical research in pancreatic cancer","volume":"8","author":"Wang","year":"2019","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.bbagen.2021.129929_bb0140","doi-asserted-by":"crossref","first-page":"889","DOI":"10.3390\/cells8080889","article-title":"Application of highly immunocompromised mice for the establishment of patient-derived xenograft (PDX) models","volume":"8","author":"Okada","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.bbagen.2021.129929_bb0145","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.5981","article-title":"A systematic review of the validity of patient derived xenograft (PDX) models: the implications for translational research and personalised medicine","volume":"6","author":"Collins","year":"2018","journal-title":"PeerJ"},{"key":"10.1016\/j.bbagen.2021.129929_bb0150","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10555-016-9653-x","article-title":"Patient-derived xenograft (pdx) models in basic and translational breast cancer research","volume":"35","author":"Dobrolecki","year":"2016","journal-title":"Cancer Metast. Rev."},{"key":"10.1016\/j.bbagen.2021.129929_bb0155","doi-asserted-by":"crossref","first-page":"50150","DOI":"10.18632\/oncotarget.10322","article-title":"Evaluation of the risk of lymphomagenesis in xenografts by the PCR-based detection of EBV BamHI W region in patient cancer specimens","volume":"7","author":"Mukohyama","year":"2016","journal-title":"Oncotarget"},{"issue":"735\u2013741","key":"10.1016\/j.bbagen.2021.129929_bb0160","article-title":"Patient-derived tumor xenografts are susceptible to formation of human lymphocytic tumors","volume":"17","author":"Bondarenko","year":"2015","journal-title":"Neoplasia"},{"key":"10.1016\/j.bbagen.2021.129929_bb0165","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/cells8050418","article-title":"Systematic review of patient-derived xenograft models for preclinical studies of anti-cancer drugs in solid tumors","volume":"8","author":"Koga","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.bbagen.2021.129929_bb0170","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nbt.2576","article-title":"Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay","volume":"31","author":"Baccelli","year":"2013","journal-title":"Nat. Biotech."},{"key":"10.1016\/j.bbagen.2021.129929_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058557","article-title":"Circulating tumor cells: application as a biomarker for molecular characterization and predictor of survival in an all-comer solid tumor phase i clinical study","volume":"8","author":"Bao","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbagen.2021.129929_bb0180","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/hep.22082","article-title":"Identification of local and circulating cancer stem cells in human liver cancer","volume":"47","author":"Yang","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.bbagen.2021.129929_bb0185","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/nm.3600","article-title":"Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer","volume":"20","author":"Hodgkinson","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbagen.2021.129929_bb0190","doi-asserted-by":"crossref","first-page":"13856","DOI":"10.1038\/s41598-017-14364-2","article-title":"Unraveling the roles of CD44\/CD24 and ALDH1 as\u00a0cancer\u00a0stem\u00a0cell\u00a0markers in tumorigenesis and\u00a0metastasis","volume":"7","author":"Li","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbagen.2021.129929_bb0195","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.50740","article-title":"Preclinical murine tumor models: a structural and functional perspective","volume":"9","author":"Guerin","year":"2020","journal-title":"eLife"},{"key":"10.1016\/j.bbagen.2021.129929_bb0200","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3390\/cells8101145","article-title":"CTC-derived models: a window into the seeding capacity of circulating tumor cells (CTCs)","volume":"8","author":"Tayoun","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.bbagen.2021.129929_bb0205","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019101654","article-title":"Xenograft and organoid model systems in cancer research","volume":"38","author":"Bleijs","year":"2019","journal-title":"EMBO J."},{"key":"10.1016\/j.bbagen.2021.129929_bb0210","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41419-019-1453-0","article-title":"Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases","volume":"10","author":"Grassi","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbagen.2021.129929_bb0215","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12935-019-1067-8","article-title":"Circulating tumor cells in\u00a0precision oncology: clinical applications in\u00a0liquid biopsy and\u00a03D organoid model","volume":"19","author":"Yang","year":"2019","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bbagen.2021.129929_bb0220","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1177\/2472555220915827","article-title":"Comparison of cell and organoid-level analysis of patient-derived 3D organoids to evaluate tumor cell growth dynamics and drug response","volume":"25","author":"Kim","year":"2020","journal-title":"SLAS Discov."},{"key":"10.1016\/j.bbagen.2021.129929_bb0225","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/biomedicines7010017","article-title":"Therapeutic targeting strategies of cancer stem cells in gastrointestinal malignancies","volume":"7","author":"Sonbol","year":"2019","journal-title":"Biomedicines"},{"key":"10.1016\/j.bbagen.2021.129929_bb0230","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.49392","article-title":"GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab","volume":"9","author":"Kato","year":"2020","journal-title":"eLife"},{"key":"10.1016\/j.bbagen.2021.129929_bb0235","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1096\/fj.201700740R","article-title":"Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy","volume":"32","author":"Wang","year":"2018","journal-title":"FASEB J."},{"key":"10.1016\/j.bbagen.2021.129929_bb0240","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1096\/fj.201601250R","article-title":"Ensuring due process in the IACUC and animal welfare setting: considerations in developing noncompliance policies and procedures for institutional animal care and use committees and institutional officials","volume":"31","author":"Hansen","year":"2017","journal-title":"FASEB J."},{"issue":"4","key":"10.1016\/j.bbagen.2021.129929_bb0245","article-title":"Ethics of animal research in human disease remediation, its institutional teaching; and alternatives to animal experimentation","volume":"5","author":"Cheluvappa","year":"2017","journal-title":"Pharma Res. Per."},{"key":"10.1016\/j.bbagen.2021.129929_bb0250","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1158\/2159-8290.CD-16-1154","article-title":"Personalized\u00a0in vitro and in vivo cancer models to guide\u00a0precision medicine","volume":"7","author":"Pauli","year":"2017","journal-title":"Cancer Discov."}],"container-title":["Biochimica et Biophysica Acta (BBA) - General Subjects"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304416521000878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304416521000878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T04:11:45Z","timestamp":1759637505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304416521000878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0304416521000878"],"URL":"https:\/\/doi.org\/10.1016\/j.bbagen.2021.129929","relation":{},"ISSN":["0304-4165"],"issn-type":[{"value":"0304-4165","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human cancer xenografts in immunocompromised mice provide an advanced genuine tumor model for research and drug development-A revisit of murine models for human cancers","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - General Subjects","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbagen.2021.129929","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"129929"}}